KAPA (Kairos Pharma, Ltd.)
Insider Trading Activity
Every open-market purchase and sale reported by KAPA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-30 | Neil Bhowmick | Chief Scientific Officer | A | — | — |
| 2025-12-23 | Hyun W. Bae | Director | A | — | — |
| 2025-11-26 | Hansoo Michael Keyoung | Director | A | — | — |
| 2025-11-26 | John S Yu | CEO and Chairman | A | — | — |
| 2025-11-26 | Ramachandran Murali | VP of Research and Development | A | — | — |
| 2025-11-26 | Rahul Singhvi | Director | A | — | — |
| 2025-11-26 | Doug Samuelson | Chief Financial Officer | A | — | — |
| 2025-04-07 | Neil Bhowmick | Chief Scientific Officer | A | — | — |
| 2025-02-24 | John S Yu | CEO and Chairman | A | — | — |
| 2025-02-24 | Ramachandran Murali | VP of Research and Development | A | — | — |
| 2024-11-25 | Ramachandran Murali | VP of Research and Development | Buy | — | — |
| 2024-11-25 | Doug Samuelson | Chief Financial Officer | Buy | — | — |
| 2024-11-21 | John S Yu | CEO and Chairman | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and Chairman | 792,382 | — |
| — | Chief Scientific Officer | 187,391 | — |
| — | VP of Research and Development | 42,790 | — |
| — | Chief Financial Officer | 41,863 | — |
| — | Director | 7,755 | — |
| — | Director | 7,029 | — |
| — | Director | 1,429 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KAPA quote page; the site-wide leaderboard is on the insider transactions hub.